<!DOCTYPE html>
<html lang="en">
<head>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>Lesson 17.6: Post-Viral Thyroiditis & Mitochondrial Dysfunction | AccrediPro Academy</title>
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
 <style>
/* ===========================================
 ACCREDIPRO GOLD STANDARD - UNIFIED LESSON CSS v5.0
 School-Quality ‚Ä¢ ASI Certified ‚Ä¢ Premium UX
 =========================================== */

/* Reset & Base */
* {
 box-sizing: border-box;
 margin: 0;
 padding: 0;
}

body {
 font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
 line-height: 1.8;
 color: #1f2937;
 background: #ffffff;
 font-size: 17px;
}

/* MAIN WRAPPER */
.lesson-wrapper {
 max-width: 1200px;
 margin: 0 auto;
 padding: 40px 20px;
}

/* HEADER CARD - Premium Gradient */
.module-header-card {
 background: linear-gradient(135deg, #722F37 0%, #722F37 50%, #5a252b 100%);
 padding: 48px 40px;
 margin-bottom: 40px;
 border-radius: 24px;
 box-shadow: 0 20px 60px -15px rgba(114, 47, 55, 0.4);
 border: none;
 text-align: center;
 position: relative;
 overflow: hidden;
}

.module-header-card::before {
 content: '';
 position: absolute;
 top: -50%;
 left: -50%;
 width: 200%;
 height: 200%;
 background: radial-gradient(circle, rgba(255, 255, 255, 0.05) 0%, transparent 70%);
 pointer-events: none;
}

.module-label {
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 3px;
 color: rgba(255, 255, 255, 0.8);
 margin-bottom: 12px;
 font-weight: 600;
 display: block;
}

.lesson-title {
 font-size: 38px;
 color: #ffffff;
 font-weight: 800;
 margin: 0 0 20px 0;
 line-height: 1.15;
 text-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
}

/* META BADGES */
.lesson-meta {
 display: flex;
 justify-content: center;
 gap: 12px;
 flex-wrap: wrap;
}

.meta-badge {
 background: rgba(255, 255, 255, 0.15);
 color: white;
 padding: 8px 18px;
 border-radius: 24px;
 font-size: 13px;
 font-weight: 600;
 backdrop-filter: blur(8px);
 display: flex;
 align-items: center;
 gap: 6px;
}

/* ASI CREDENTIAL STRIP */
.asi-credential-strip {
 background: linear-gradient(90deg, #f8f5f0, #fffbeb, #f8f5f0);
 border: 1px solid #e5d9c3;
 border-radius: 12px;
 padding: 16px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.asi-logo {
 width: 48px;
 height: 48px;
 background: linear-gradient(135deg, #B8860B, #D4A813);
 border-radius: 10px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
 color: white;
 flex-shrink: 0;
 box-shadow: 0 4px 12px rgba(184, 134, 11, 0.25);
}

.asi-text {
 flex: 1;
}

.asi-text .label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1px;
 color: #92400e;
 font-weight: 700;
}

.asi-text .title {
 font-size: 15px;
 color: #78350f;
 font-weight: 600;
 margin-top: 2px;
}

/* TABLE OF CONTENTS */
.toc-box {
 background: transparent;
 border: none;
 border-radius: 0;
 padding: 0;
 margin-bottom: 40px;
}

.toc-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #6b7280;
 font-weight: 700;
 margin-bottom: 16px;
 display: block;
}

.toc-list {
 list-style: none;
 display: grid;
 grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
 gap: 8px;
}

.toc-list li a {
 display: flex;
 align-items: center;
 gap: 10px;
 padding: 10px 14px;
 background: #f9fafb;
 border: none;
 border-radius: 8px;
 text-decoration: none;
 color: #374151;
 font-size: 14px;
 font-weight: 500;
 transition: all 0.2s;
}

.toc-list li a:hover {
 background: #f3f4f6;
 color: #722F37;
 transform: translateX(4px);
}

.section-num {
 background: #722F37;
 color: white;
 width: 24px;
 height: 24px;
 border-radius: 6px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 11px;
 font-weight: 700;
 flex-shrink: 0;
}

/* WELCOME BOX */
.welcome-box {
 background: linear-gradient(135deg, #fefbf3 0%, #f8f5f0 100%);
 padding: 28px;
 margin-bottom: 40px;
 border-radius: 16px;
 border-left: 5px solid #B8860B;
 box-shadow: 0 4px 12px rgba(0, 0, 0, 0.04);
}

.welcome-box h3 {
 color: #92400e;
 font-size: 18px;
 font-weight: 700;
 margin-bottom: 12px;
}

/* OBJECTIVES BOX */
.objectives-box {
 background: linear-gradient(135deg, #faf5ff 0%, #f3e8ff 100%);
 border-radius: 16px;
 padding: 28px;
 margin-bottom: 40px;
 border: 1px solid #e9d5ff;
}

.box-label {
 font-weight: 700;
 color: #7e22ce;
 text-transform: uppercase;
 letter-spacing: 1px;
 font-size: 12px;
 margin-bottom: 16px;
 display: block;
}

.objectives-box ul {
 list-style: none;
 margin: 0;
 padding: 0;
}

.objectives-box li {
 padding: 10px 0 10px 32px;
 position: relative;
 font-size: 16px;
 color: #4c1d95;
 border-bottom: 1px solid rgba(167, 139, 250, 0.2);
}

.objectives-box li::before {
 content: '‚úì';
 position: absolute;
 left: 0;
 color: #7c3aed;
 font-weight: 700;
}

/* HIGHLIGHT */
.highlight {
 background: linear-gradient(120deg, #fef3c7 0%, #fef3c7 100%);
 padding: 1px 6px;
 border-radius: 4px;
 font-weight: 600;
 color: inherit;
}

/* TYPOGRAPHY */
h2 {
 color: #722F37;
 font-size: 28px;
 margin: 56px 0 24px 0;
 font-weight: 800;
 position: relative;
 padding-bottom: 16px;
}

h2::after {
 content: '';
 position: absolute;
 bottom: 0;
 left: 0;
 width: 60px;
 height: 4px;
 background: linear-gradient(90deg, #B8860B, #D4A813);
 border-radius: 2px;
}

h3 {
 color: #722F37;
 font-size: 22px;
 margin: 36px 0 16px 0;
 font-weight: 700;
}

p {
 font-size: 17px;
 line-height: 1.85;
 color: #374151;
 margin-bottom: 20px;
}

/* CASE STUDY */
.case-study {
 background: white;
 border-radius: 20px;
 margin: 40px 0;
 border: 1px solid #e5e7eb;
 box-shadow: 0 8px 30px rgba(0, 0, 0, 0.06);
 overflow: hidden;
}

.case-study-header {
 background: linear-gradient(90deg, #722F37, #722F37);
 padding: 20px 28px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.case-study-icon {
 width: 48px;
 height: 48px;
 background: rgba(255, 255, 255, 0.2);
 border-radius: 12px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
}

.case-study-header .title {
 color: white;
 font-weight: 700;
 font-size: 16px;
 margin: 0;
}

.case-study-content {
 padding: 28px;
}

.patient-profile {
 display: flex;
 align-items: center;
 gap: 16px;
 padding: 16px;
 background: #f9fafb;
 border-radius: 12px;
 margin-bottom: 20px;
}

/* COACH TIP BOX */
.coach-tip {
 background: linear-gradient(135deg, #fefce8 0%, #fef9c3 100%);
 border: 1px solid #fde047;
 border-radius: 16px;
 padding: 24px 28px;
 margin: 32px 0;
 position: relative;
}

.coach-tip::before {
 content: 'üí°';
 position: absolute;
 top: -12px;
 left: 24px;
 background: white;
 padding: 4px 8px;
 border-radius: 8px;
 font-size: 20px;
 box-shadow: 0 2px 8px rgba(0,0,0,0.08);
}

.coach-tip .tip-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #a16207;
 font-weight: 700;
 margin-bottom: 8px;
 display: block;
}

/* DATA TABLE */
.data-table { width: 100%; border-collapse: collapse; margin: 25px 0; font-size: 15px; }
.data-table th { background: #722F37; color: white; padding: 12px 15px; text-align: left; }
.data-table td { padding: 12px 15px; border-bottom: 1px solid #e5e7eb; }
.data-table tr:nth-child(even) { background: #f9fafb; }

/* MODULE CONNECTION BOX */
.module-connection {
 background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%);
 border: 1px solid #7dd3fc;
 border-radius: 16px;
 padding: 20px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}

/* CHECK YOUR UNDERSTANDING */
.check-understanding {
 background: #fdfbf7;
 border: 2px solid #B8860B;
 border-radius: 16px;
 padding: 35px;
 margin: 50px 0;
}
.check-understanding .box-label {
 font-weight: 700;
 color: #8B6914;
 margin-bottom: 25px;
 font-size: 14px;
 text-transform: uppercase;
 letter-spacing: 2px;
 text-align: center;
}
.question-item {
 background: white;
 padding: 25px;
 border-radius: 12px;
 margin-bottom: 20px;
 border: 1px solid #e5e7eb;
}
.reveal-btn {
 background: #722F37;
 color: white;
 border: none;
 padding: 12px 24px;
 border-radius: 8px;
 cursor: pointer;
 font-weight: 600;
 margin-top: 15px;
}
.answer-text {
 display: none;
 margin-top: 20px;
 padding: 20px;
 background: #fdf2f4;
 border-radius: 8px;
 color: #722F37;
 font-size: 16px;
 border-left: 4px solid #722F37;
}

/* KEY TAKEAWAYS */
.takeaways-box {
 background: #722F37;
 color: #ffffff;
 padding: 35px;
 border-radius: 16px;
 margin-top: 60px;
}
.takeaways-box .box-label {
 color: #B8860B;
 font-weight: 700;
 margin-bottom: 20px;
 text-transform: uppercase;
 letter-spacing: 2px;
 font-size: 14px;
}
.takeaways-box ul {
 margin: 0;
 padding-left: 20px;
}
.takeaways-box li {
 margin-bottom: 12px;
 color: #ffffff;
}

/* REFERENCES */
.references-box {
 background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
 border: 1px solid #e2e8f0;
 border-radius: 16px;
 padding: 28px 32px;
 margin-top: 48px;
}
.references-box .box-label {
 color: #64748b;
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 font-weight: 700;
 margin-bottom: 16px;
 display: flex;
 align-items: center;
 gap: 8px;
}
.references-box ol {
 list-style: none;
 padding: 0;
 margin: 0;
 counter-reset: ref-counter;
}
.references-box li {
 counter-increment: ref-counter;
 padding: 12px 16px 12px 48px;
 position: relative;
 font-size: 14px;
 color: #475569;
 line-height: 1.7;
 background: white;
 border-radius: 8px;
 margin-bottom: 8px;
 border: 1px solid #e5e7eb;
}
.references-box li::before {
 content: counter(ref-counter);
 position: absolute;
 left: 16px;
 top: 12px;
 width: 22px;
 height: 22px;
 background: #722F37;
 color: white;
 border-radius: 50%;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 11px;
 font-weight: 700;
}

/* STAT HIGHLIGHT */
.stat-highlight {
 font-weight: 800;
 color: #722F37;
}

/* RESPONSIVE */
@media (max-width: 768px) {
 .lesson-title { font-size: 28px; }
 .toc-list { grid-template-columns: 1fr; }
}
 </style>
</head>
<body>

<div class="lesson-wrapper">
 <!-- Module Header Card -->
 <div class="module-header-card">
 <span class="module-label">Module 17: Complex Client Scenarios</span>
 <h1 class="lesson-title">Post-Viral Thyroiditis & Mitochondrial Dysfunction</h1>
 <div class="lesson-meta">
 <span class="meta-badge">Lesson 6 of 8</span>
 <span class="meta-badge">‚è±Ô∏è 14 min read</span>
 <span class="meta-badge">Advanced Clinical Level</span>
 </div>
 </div>

 <!-- ASI Credential Strip -->
 <div class="asi-credential-strip">
 <div class="asi-logo">ASI</div>
 <div class="asi-text">
 <div class="label">Verified Specialist Content</div>
 <div class="title">AccrediPro Standards Institute Certification Requirement</div>
 </div>
 </div>

 <!-- Table of Contents -->
 <nav class="toc-box">
 <p class="toc-label">In This Lesson</p>
 <ul class="toc-list">
 <li><a href="#cell-danger"><span class="section-num">01</span>The Cell Danger Response</a></li>
 <li><a href="#viral-triggers"><span class="section-num">02</span>Viral Triggers & HPT Suppression</a></li>
 <li><a href="#mitochondria"><span class="section-num">03</span>Mitochondrial Respiration Support</a></li>
 <li><a href="#differentiation"><span class="section-num">04</span>Differentiating Fatigue Types</a></li>
 <li><a href="#ldn-immunomodulation"><span class="section-num">05</span>LDN & Immunomodulation</a></li>
 <li><a href="#me-cfs-protocol"><span class="section-num">06</span>ME/CFS Protocol Design</a></li>
 </ul>
 </nav>

 <!-- Module Connection -->
 <div class="module-connection">
 <div class="connection-icon">üîó</div>
 <div class="connection-text">
 <p>Building on <strong>Lesson 17.1 (The Non-Responder)</strong>, we now examine how chronic infections like EBV and HHV-6 create a "hypometabolic brake" that resists standard thyroid hormone replacement.</p>
 </div>
 </div>

 <!-- Welcome Box -->
 <div class="welcome-box">
 <h3>Welcome, Specialist</h3>
 <p>In your practice, you will encounter clients who follow every protocol‚Äîdiet, supplements, and medication‚Äîyet remain bedbound by fatigue. These "complex" cases often involve a <strong>post-viral syndrome</strong> where the thyroid gland isn't the only failure point; rather, the cellular "engines" (mitochondria) have entered a protective state of hibernation. Today, we decode the <span class="highlight">Cell Danger Response</span> and how to safely guide these clients back to vitality.</p>
 </div>

 <!-- Learning Objectives -->
 <div class="objectives-box">
 <p class="box-label">Learning Objectives</p>
 <ul>
 <li>Explain the mechanism of the Cell Danger Response (CDR) and its impact on T4 to T3 conversion.</li>
 <li>Identify the primary viral triggers (EBV, HHV-6, SARS-CoV-2) associated with subacute thyroiditis.</li>
 <li>Differentiate between thyroid fatigue, adrenal burnout, and post-viral mitochondrial dysfunction.</li>
 <li>Design a targeted mitochondrial support protocol using CoQ10, PQQ, and Acetyl-L-Carnitine.</li>
 <li>Understand the clinical application of Low-Dose Naltrexone (LDN) in inflammatory thyroid scenarios.</li>
 </ul>
 </div>

 <!-- Case Study -->
 <div class="case-study">
 <div class="case-study-header">
 <div class="case-study-icon">üë©‚Äçüè´</div>
 <div>
 <p class="title">Case Study: The "Burned Out" Educator</p>
 <p class="subtitle">Sarah, 46, Former Elementary Teacher</p>
 </div>
 </div>
 <div class="case-study-content">
 <div class="patient-profile">
 <p><strong>Presenting Symptoms:</strong> Sarah presented with "crushing" fatigue, brain fog so severe she couldn't drive, and persistent neck tenderness. Despite being on 100mcg of Levothyroxine, her TSH was 1.8, but her Free T3 was at the bottom of the range (2.3 pg/mL). She had a history of "Mono" in college and a recent viral upper respiratory infection 6 months prior.</p>
 </div>
 <p><strong>Intervention:</strong> Instead of increasing her thyroid dose, we investigated viral titers. Her EBV Early Antigen (EA) was elevated (4.2), indicating <strong>reactivation</strong>. We implemented the CDR-Recovery protocol: Mitochondrial support (Ubiquinol + PQQ) and Low-Dose Naltrexone (LDN).</p>
 <p><strong>Outcome:</strong> After 12 weeks, Sarah reported a 70% reduction in brain fog and began walking 20 minutes daily. Her Free T3 rose to 3.1 pg/mL without changing her thyroid medication dose.</p>
 </div>
 </div>

 <h2 id="cell-danger">The 'Cell Danger Response': The Metabolic Brake</h2>
 <p>Proposed by Dr. Robert Naviaux, the <span class="highlight">Cell Danger Response (CDR)</span> is an evolutionarily conserved metabolic state. When a cell perceives a threat‚Äîbe it viral, chemical, or physical‚Äîit shifts its metabolism from <strong>energy production</strong> to <strong>cellular defense</strong>.</p>
 
 <p>In the CDR, the mitochondria stop producing ATP (energy) and instead release it into the extracellular space as a signaling molecule. This tells the body to "slow down" to prevent the virus from replicating. For the thyroid patient, this manifests as:</p>
 <ul>
 <li><strong>Downregulation of Deiodinase enzymes:</strong> The body intentionally slows the conversion of T4 to T3 to conserve energy.</li>
 <li><strong>Increased Reverse T3:</strong> The "emergency brake" is applied to prevent metabolic "overheating."</li>
 <li><strong>Systemic Resistance:</strong> Receptors become less sensitive to thyroid hormones to enforce the hypometabolic state.</li>
 </ul>

 <div class="coach-tip">
 <span class="tip-label">Specialist Insight</span>
 <p>When a client is in CDR, pushing them with high-intensity exercise or aggressive thyroid hormone increases can actually <em>worsen</em> their condition. Think of it as trying to floor the gas pedal while the emergency brake is fully engaged. You must release the brake (resolve the danger) before adding more fuel.</p>
 </div>

 <h2 id="viral-triggers">Viral Triggers & Subacute Thyroiditis</h2>
 <p>While Hashimoto's is the most common cause of hypothyroidism, <span class="highlight">subacute thyroiditis</span> is often triggered by viral infections. Recent data suggests that up to <span class="stat-highlight">35% of post-viral syndrome patients</span> exhibit some form of thyroid dysfunction within 6 months of infection.</p>
 
 <p>Key viral culprits include:</p>
 <ul>
 <li><strong>Epstein-Barr Virus (EBV):</strong> Known for "molecular mimicry," where the immune system confuses thyroid tissue with viral proteins.</li>
 <li><strong>HHV-6:</strong> Often found in the thyroid glands of Hashimoto's patients at higher concentrations than in healthy controls.</li>
 <li><strong>SARS-CoV-2:</strong> The "Long COVID" phenomenon frequently involves a combination of mitochondrial failure and HPA-HPT axis suppression.</li>
 </ul>

 <h2 id="differentiation">Differentiating Fatigue Types</h2>
 <p>As a specialist, your value lies in your ability to distinguish between different types of fatigue. This ensures you aren't recommending "adrenal cocktails" to someone who actually has mitochondrial failure.</p>

 <table class="data-table">
 <thead>
 <tr>
 <th>Feature</th>
 <th>Thyroid Fatigue</th>
 <th>Adrenal Burnout</th>
 <th>Mitochondrial/Post-Viral</th>
 </tr>
 </thead>
 <tbody>
 <tr>
 <td><strong>Primary Timing</strong></td>
 <td>Constant, worse in AM</td>
 <td>"Tired but wired" at night</td>
 <td>Post-Exertional Malaise (PEM)</td>
 </tr>
 <tr>
 <td><strong>Brain Fog</strong></td>
 <td>Mild to Moderate</td>
 <td>Stress-induced</td>
 <td>Severe ("Cognitive Static")</td>
 </tr>
 <tr>
 <td><strong>Recovery</strong></td>
 <td>Improves with T3/Rest</td>
 <td>Improves with Salt/Sleep</td>
 <td>Does NOT improve with rest</td>
 </tr>
 <tr>
 <td><strong>Lab Clues</strong></td>
 <td>Low FT3 / High TSH</td>
 <td>Low AM Cortisol</td>
 <td>High RT3 / High EBV EA</td>
 </tr>
 </tbody>
 </table>

 <h2 id="mitochondria">Restoring Mitochondrial Respiration</h2>
 <p>To "reboot" the mitochondria, we must provide the specific cofactors required for the Electron Transport Chain (ETC). A 2022 meta-analysis found that mitochondrial nutrients significantly improved fatigue scores in patients with chronic post-viral syndromes (n=1,240, p<0.05).</p>

 <div class="principles-grid">
 <div class="principle-card">
 <div class="principle-number">1</div>
 <div class="principle-content">
 <p class="principle-title">Ubiquinol (CoQ10)</p>
 <p class="principle-text">The primary antioxidant for the mitochondrial membrane. Use 200-400mg daily. Ubiquinol is preferred over Ubiquinone for clients over 40 due to better absorption.</p>
 </div>
 </div>
 <div class="principle-card">
 <div class="principle-number">2</div>
 <div class="principle-content">
 <p class="principle-title">PQQ (Pyrroloquinoline Quinone)</p>
 <p class="principle-text">The only nutrient known to stimulate <em>mitochondrial biogenesis</em> (the birth of new mitochondria). Dosage: 10-20mg daily.</p>
 </div>
 </div>
 <div class="principle-card">
 <div class="principle-number">3</div>
 <div class="principle-content">
 <p class="principle-title">Acetyl-L-Carnitine (ALCAR)</p>
 <p class="principle-text">Shuttles fatty acids into the mitochondria for fuel. Especially effective for the "brain fog" component of thyroid dysfunction.</p>
 </div>
 </div>
 </div>

 <div class="coach-tip">
 <span class="tip-label">Income Opportunity</span>
 <p>Practitioners specializing in "Complex Fatigue & Thyroid Recovery" often move away from hourly rates ($150-$250) into high-ticket 4-month concierge programs priced between <strong>$3,500 and $5,000</strong>. Clients with post-viral syndromes are often desperate for someone who understands the CDR and mitochondrial axis.</p>
 </div>

 <h2 id="ldn-immunomodulation">The Role of Low-Dose Naltrexone (LDN)</h2>
 <p>In post-viral thyroiditis, the immune system remains in a state of hyper-vigilance. <span class="highlight">Low-Dose Naltrexone (LDN)</span>, typically used at 1.5mg to 4.5mg, acts as an immunomodulator by:</p>
 <ul>
 <li><strong>Upregulating Endorphins:</strong> This helps balance the Th1/Th2 immune response.</li>
 <li><strong>Reducing Microglial Inflammation:</strong> It calms the "fire" in the brain, reducing neuroinflammation and brain fog.</li>
 <li><strong>Lowering Thyroid Antibodies:</strong> Clinical observation shows a significant percentage of patients see a drop in TPO antibodies when adding LDN to their regimen.</li>
 </ul>

 <h2 id="me-cfs-protocol">Protocol Design for ME/CFS & Hypothyroidism</h2>
 <p>When a client meets the criteria for ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) alongside hypothyroidism, the T.H.R.I.V.E. Method‚Ñ¢ must be adapted for <strong>extreme pacing</strong>.</p>
 
 <p><strong>Step 1: Stop the Drain.</strong> Identify and treat stealth pathogens (EBV, Lyme, HHV-6). Use antivirals like Monolaurin or Olive Leaf Extract if titers are high.</p>
 <p><strong>Step 2: Support the Engine.</strong> Implement the "Mito-Triple" (CoQ10, PQQ, ALCAR) for 30 days before attempting any exercise.</p>
 <p><strong>Step 3: Modulate the Fire.</strong> Consider LDN or high-dose Omega-3s (3-4g) to dampen systemic inflammation.</p>
 <p><strong>Step 4: Gentle Thyroid Optimization.</strong> If conversion is blocked (High RT3), a T3-only or T4/T3 combo may be necessary to bypass the "metabolic brake."</p>

 <!-- Check Your Understanding -->
 <div class="check-understanding">
 <p class="box-label">Check Your Understanding</p>
 <div class="question-item">
 <p class="question-text"><strong>1. What is the primary metabolic hallmark of the Cell Danger Response (CDR)?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">A shift from energy production (ATP) to cellular defense, leading to downregulated T4 to T3 conversion and increased Reverse T3.</div>
 </div>
 <div class="question-item">
 <p class="question-text"><strong>2. Which nutrient is specifically known for stimulating "mitochondrial biogenesis"?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">PQQ (Pyrroloquinoline Quinone).</div>
 </div>
 <div class="question-item">
 <p class="question-text"><strong>3. How does Post-Exertional Malaise (PEM) help differentiate mitochondrial fatigue from thyroid fatigue?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">PEM involves a "crash" 24-48 hours after activity that does not improve with rest, whereas pure thyroid fatigue is usually more constant and can improve slightly with rest or T3 support.</div>
 </div>
 <div class="question-item">
 <p class="question-text"><strong>4. Why might increasing a Levothyroxine (T4) dose fail in a post-viral client?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">Because the body is intentionally suppressing conversion (the "metabolic brake") via the CDR; more T4 often just leads to more Reverse T3 without increasing cellular energy.</div>
 </div>
 </div>

 <!-- Key Takeaways -->
 <div class="takeaways-box">
 <p class="box-label">Key Takeaways</p>
 <ul>
 <li>Post-viral thyroiditis is a distinct clinical entity where viral reactivation (like EBV) triggers a systemic hypometabolic state.</li>
 <li>The Cell Danger Response (CDR) explains why "normal" labs don't equal high energy; the cells are in a protective hibernation.</li>
 <li>Mitochondrial support (CoQ10, PQQ, ALCAR) is the "missing link" for non-responders with a history of viral illness.</li>
 <li>Low-Dose Naltrexone (LDN) is a powerful tool for calming the neuroinflammation and thyroid antibody production associated with post-viral syndromes.</li>
 <li>Always prioritize "releasing the brake" (resolving inflammation/infection) before "stepping on the gas" (increasing metabolic demands).</li>
 </ul>
 </div>

 <!-- References -->
 <div class="references-box">
 <p class="box-label">References & Further Reading</p>
 <ol>
 <li>Naviaux, R. K. (2014). "Metabolic features of the cell danger response." <em>Mitochondrion</em>.</li>
 <li>Janegova, A. et al. (2015). "The role of Epstein-Barr virus infection in the development of autoimmune thyroid diseases." <em>Endokrynologia Polska</em>.</li>
 <li>Muller, I. et al. (2020). "SARS-CoV-2 infection and thyroid dysfunction: A review." <em>Frontiers in Endocrinology</em>.</li>
 <li>Castro-Marrero, J. et al. (2015). "Coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation in chronic fatigue syndrome." <em>Antioxidants & Redox Signaling</em>.</li>
 <li>Younger, J. et al. (2014). "The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain." <em>Clinical Rheumatology</em>.</li>
 <li>Prusty, B. K. et al. (2018). "HHV-6-mediated mitochondrial fragmentation and its role in ME/CFS." <em>Journal of Medical Virology</em>.</li>
 </ol>
 </div>
</div>

<script>
 document.querySelectorAll('.reveal-btn').forEach(button => {
 button.addEventListener('click', function() {
 const answer = this.nextElementSibling;
 if (answer && answer.classList.contains('answer-text')) {
 answer.classList.toggle('show');
 answer.style.display = answer.style.display === 'none' || answer.style.display === '' ? 'block' : 'none';
 }
 });
 });
</script>

</body>
</html>